COST-EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN RUSSIAN FEDERATION

被引：0
|
作者：
Yagudina, R. [1 ]
Kulikov, A. [1 ]
Komarov, I [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2132
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A426 / A426
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012
    Romero, Martin
    Chavez, Diana
    De los Rios, Magali
    Alvis-Guzman, Nelson
    BIOMEDICA, 2014, 34 (01): : 48 - 59
  • [32] SUPERIOR EFFICACY OF NILOTINIB COMPARED WITH IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH PH plus CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND 3-YEAR FOLLOW-UP
    Clark, R.
    Reiffers, J.
    Kim, D. W.
    Rosti, G.
    Kurokawa, M.
    Moiraghi, B.
    Larson, R.
    Saglio, G.
    Hughes, T.
    Woodman, R.
    Blakesley, R.
    Kemp, C.
    Kantarjian, H.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 237 - 237
  • [33] Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive (PH plus ) Chronic Myeloid Leukemia (CML) or PH plus Acute Lymphoblastic Leukemia (ALL): a Pharmacokinetic Study
    Hijiya, Nobuko
    Zwaan, C. Michel
    Rizzari, Carmelo
    Foa, Roberto
    Abbink, Floor
    Lancaster, Donna
    Landman-Parker, Judith
    Millot, Frederic
    Moppett, John
    Nelken, Brigitte
    Ducassou, Stephane
    Putti, Maria Caterina
    Tian, Xianbin
    Sinclair, Karen
    Santanastasio, Helene
    Buchbinder, Aby
    Kearns, Pamela
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S34 - S34
  • [34] Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Jones, Dan
    Ferrajoli, Alessandra
    Konopleva, Marina
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Letvak, Laurie A.
    Kantarjian, Hagop
    BLOOD, 2008, 112 (11) : 170 - 170
  • [35] Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs)
    Hughes, Timothy
    Mauro, Michael
    Kim, Dong-Wook
    Cortes, Jorge
    Rea, Delphine
    Minami, Hironobu
    Breccia, Massimo
    DeAngelo, Daniel
    Hochhaus, Andreas
    Goh, Yeow-Tee
    le Coutre, Philipp
    Lang, Fabian
    Cacciatore, Silvia
    Aimone, Paola
    Stenson, Laura
    Polydoros, Fotis
    Talpaz, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S235 - S235
  • [36] Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China
    Li, Na
    Zheng, Bin
    Cai, Hong-Fu
    Yang, Jing
    Luo, Xiao-Feng
    Weng, Li-Zhu
    Zhan, Feng-Mei
    Liu, Mao-Bai
    CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 79 - 86
  • [37] Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China
    Na Li
    Bin Zheng
    Hong-Fu Cai
    Jing Yang
    Xiao-Feng Luo
    Li-Zhu Weng
    Feng-Mei Zhan
    Mao-Bai Liu
    Clinical Drug Investigation, 2018, 38 : 79 - 86
  • [38] Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph plus CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data
    Li, Nanxin
    Yang, Chelsey
    Fan, Liangyi
    Totev, Todor
    Guerin, Annie
    Chen, Lei
    BLOOD, 2015, 126 (23)
  • [39] EFFICACY AND SAFETY OF NILOTINIB IN OLDER (≥65 YEARS) PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): RESULTS FROM THE PHASE 3 ENESTND (EVALUATING NILOTINIB EFFICACY AND SAFETY IN CLINICAL TRIALS OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE CML PATIENTS) STUDY.
    Gorospe, Gerry
    Kantarjian, H. Hagop
    Hochhaus, Andreas
    Larson, Richard
    Saglio, Giuseppe
    Hughes, Timothy
    ONCOLOGY NURSING FORUM, 2012, 39 (03) : E191 - E192
  • [40] Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
    Larson, R. A.
    Hochhaus, A.
    Hughes, T. P.
    Clark, R. E.
    Etienne, G.
    Kim, D-W
    Flinn, I. W.
    Kurokawa, M.
    Moiraghi, B.
    Yu, R.
    Blakesley, R. E.
    Gallagher, N. J.
    Saglio, G.
    Kantarjian, H. M.
    LEUKEMIA, 2012, 26 (10) : 2197 - 2203
12345